• Something wrong with this record ?

Bioluminescent Zebrafish Transplantation Model for Drug Discovery

M. Hason, J. Jovicic, I. Vonkova, M. Bojic, T. Simon-Vermot, RM. White, P. Bartunek

. 2022 ; 13 (-) : 893655. [pub] 20220427

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22017290

In the last decade, zebrafish have accompanied the mouse as a robust animal model for cancer research. The possibility of screening small-molecule inhibitors in a large number of zebrafish embryos makes this model particularly valuable. However, the dynamic visualization of fluorescently labeled tumor cells needs to be complemented by a more sensitive, easy, and rapid mode for evaluating tumor growth in vivo to enable high-throughput screening of clinically relevant drugs. In this study we proposed and validated a pre-clinical screening model for drug discovery by utilizing bioluminescence as our readout for the determination of transplanted cancer cell growth and inhibition in zebrafish embryos. For this purpose, we used NanoLuc luciferase, which ensured rapid cancer cell growth quantification in vivo with high sensitivity and low background when compared to conventional fluorescence measurements. This allowed us large-scale evaluation of in vivo drug responses of 180 kinase inhibitors in zebrafish. Our bioluminescent screening platform could facilitate identification of new small-molecules for targeted cancer therapy as well as for drug repurposing.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017290
003      
CZ-PrNML
005      
20220720100156.0
007      
ta
008      
220718s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2022.893655 $2 doi
035    __
$a (PubMed)35559262
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Hason, Martina $u Laboratory of Cell Differentiation, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czechia
245    10
$a Bioluminescent Zebrafish Transplantation Model for Drug Discovery / $c M. Hason, J. Jovicic, I. Vonkova, M. Bojic, T. Simon-Vermot, RM. White, P. Bartunek
520    9_
$a In the last decade, zebrafish have accompanied the mouse as a robust animal model for cancer research. The possibility of screening small-molecule inhibitors in a large number of zebrafish embryos makes this model particularly valuable. However, the dynamic visualization of fluorescently labeled tumor cells needs to be complemented by a more sensitive, easy, and rapid mode for evaluating tumor growth in vivo to enable high-throughput screening of clinically relevant drugs. In this study we proposed and validated a pre-clinical screening model for drug discovery by utilizing bioluminescence as our readout for the determination of transplanted cancer cell growth and inhibition in zebrafish embryos. For this purpose, we used NanoLuc luciferase, which ensured rapid cancer cell growth quantification in vivo with high sensitivity and low background when compared to conventional fluorescence measurements. This allowed us large-scale evaluation of in vivo drug responses of 180 kinase inhibitors in zebrafish. Our bioluminescent screening platform could facilitate identification of new small-molecules for targeted cancer therapy as well as for drug repurposing.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jovicic, Jovana $u Laboratory of Cell Differentiation, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Vonkova, Ivana $u CZ-OPENSCREEN, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Bojic, Milan $u CZ-OPENSCREEN, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czechia
700    1_
$a Simon-Vermot, Theresa $u Department of Cancer Biology & Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, United States $u Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States
700    1_
$a White, Richard M $u Department of Cancer Biology & Genetics, Memorial Sloan Kettering Cancer Center, New York, NY, United States $u Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States
700    1_
$a Bartunek, Petr $u Laboratory of Cell Differentiation, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czechia $u CZ-OPENSCREEN, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czechia
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 13, č. - (2022), s. 893655
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35559262 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100151 $b ABA008
999    __
$a ind $b bmc $g 1816522 $s 1168532
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 13 $c - $d 893655 $e 20220427 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
LZP    __
$a Pubmed-20220718

Find record

Citation metrics

Archiving options